COMP <GO>
LH vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Labcorp Holdings Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LH 5
— JNJ 9
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $361.39 (-1.84%) • MKT CAP: $29.86B
balance-sheet
3.58
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.80% | 67.90% | -39.10 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.30% | 25.50% | -17.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.6x | 18.5x | +1.10 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 4.04% | 2.97% | +1.07 | LH | /fcf-yield <GO> |
| Operating Margin | 9.90% | 34.70% | -24.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 6.30% | 28.50% | -22.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 7.20% | 6.00% | +1.20 | LH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.81% | 0.00% | +0.81 | LH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.58 | 5.59 | -2.01 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.20% | -0.40 | LH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 74.5 | 60.4 | +14.19 | LH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.08 | -0.12 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.6x | 23.0x | +8.60 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.86B | $662.49B | -$632.63B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LH REV | JNJ REV | LH GROSS % | JNJ GROSS % | LH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.95B | $94.19B | 28.8% | 67.9% | $1.21B | $19.70B |
| FY 2024 | $13.01B | $88.82B | 27.9% | 69.1% | $1.10B | $19.84B |
| FY 2023 | $12.16B | $85.16B | 44.0% | 44.0% | $780.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LH // BETA 0.96
JNJ // BETA 1.08